BACKGROUND: @entity6 is widely considered to be associated with @entity788 . OBJECTIVE: To determine the incidence of @entity788 in new-onset type 2 @entity6 @entity1 by measuring the serum level of CA 19-9 and performing abdominal ultrasonography (US). @entity1 AND METHODS: Consecutive type 2 @entity6 @entity1 in whom @entity6 was diagnosed within 36 months were included in this prospective study. Serum CA 19-9 measurement and US were performed in all @entity1 . If any of two was positive, abdominal computer tomography (CT) was carried out. Endoscopic ultrasound-guided fine needle aspiration or direct surgical referral was performed on @entity1 with CT-identified lesions. RESULTS: A total of 115 @entity1 were enrolled. CA 19-9 was elevated in 10 @entity1 but @entity788 diagnosed in neither of them. @entity788 was revealed by morphological means in three @entity1 without elevated CA 19-9 level. The sensitivity, specificity, positive-, negative predictive values and validity were 0%, 90.4%, 0%, 97.9% and 87.9% for CA 19-9, 66.7%, 100%, 100%, 99% and 99% for US, respectively. The value of the Standardized Incidence Ratio for @entity788 in new-onset type-2 @entity6 @entity1 was 198.6 (95% CI  =  6.25-46.9). CONCLUSIONS: The prevalence of @entity788 in @entity1 with new-onset type-2 @entity6 is significantly higher than that in the general population and screening is beneficial for detecting PaC in this @entity1 population. CA 19-9 and US is not reliable screening modality for @entity788 screening in this population.

New-onset XXXX - A high-risk group suitable for the screening of @entity788 ?

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic cancer', 'pancreatic cancer'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes', 'Type 2 diabetes mellitus']
@entity6 :: (MESH:D003920,Disease) :: ['type 2 diabetes mellitus']
